Cargando…

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes

Mobocertinib is an oral tyrosine kinase inhibitor (TKI) that selectively targets epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations. It is a structural analog of the third-generation TKI osimertinib, which targets EGFR T790M mutant non-small cell lung cancer (NSCLC); however,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnold, Abram, Ganti, Apar Kishor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349594/ https://www.ncbi.nlm.nih.gov/pubmed/37456145 http://dx.doi.org/10.2147/OTT.S374489

Ejemplares similares

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
por: Garcia Campelo, Maria Rosario, et al.
Publicado: (2022)

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
por: Imran, Mohd, et al.
Publicado: (2021)

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
por: Macha, Muzafar A, et al.
Publicado: (2013)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Reade, Chad A, et al.
Publicado: (2009)

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study
por: Gupta, Neeraj, et al.
Publicado: (2022)

Current concepts in the management of small cell lung cancer
por: Ganti, Apar Kishor, et al.
Publicado: (2013)

Promising trends in lung cancer care, but are we overlooking the majority?
por: Sharma, Bhavina, et al.
Publicado: (2023)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database
por: Anggondowati, Trisari, et al.
Publicado: (2020)

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

Pancytopenia due to iron deficiency worsened by iron infusion: a case report
por: Ganti, Apar Kishor, et al.
Publicado: (2007)

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
por: Kamel, Josette, et al.
Publicado: (2021)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo, Alessia E, et al.
Publicado: (2017)

Weight Loss and Percutaneous Endoscopic Gastrostomy Tube Placement during Chemoradiotherapy for Locally Advanced Cancer of the Oropharynx Do Not Negatively Impact Outcomes
por: Baine, Michael J., et al.
Publicado: (2017)

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations
por: Wang, Jun, et al.
Publicado: (2022)

Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

Exertional Chest Pain and Dyspnea From Hyperviscosity Syndrome Related to Marginal Zone Lymphoma
por: Dhakal, Prajwal, et al.
Publicado: (2014)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
por: Zhang, Steven, et al.
Publicado: (2021)

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
por: Han, Han, et al.
Publicado: (2021)

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
por: Petrini, Iacopo, et al.
Publicado: (2022)

Risk of malignancy in patients with chronic kidney disease
por: Tendulkar, Ketki K., et al.
Publicado: (2022)

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
por: Galvez‐Nino, Marco, et al.
Publicado: (2022)

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
por: Zhou, Caicun, et al.
Publicado: (2021)

Characterizing Immune Checkpoint Inhibitor-Induced Hypophysitis and Obstacles in Diagnosis
por: Johnson, Jake, et al.
Publicado: (2021)

Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes
por: Roof, Logan, et al.
Publicado: (2023)

RNA-based therapies: A cog in the wheel of lung cancer defense
por: Khan, Parvez, et al.
Publicado: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC)
por: Potti, Anil, et al.
Publicado: (2005)

Characteristics of toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced non-small cell lung cancer: a pooled analysis based on individual patient data of CALGB/Alliance trials
por: Yang, Lexie Zidanyue, et al.
Publicado: (2022)

Risk factors of SARS-CoV-2 infection and complications from COVID-19 in lung cancer patients
por: Ganti, Apar Kishor, et al.
Publicado: (2023)

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
por: Jia, Keyi, et al.
Publicado: (2022)

Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes
por: Moreno Vanegas, Yenny, et al.
Publicado: (2022)

The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations
por: Hernandez, Luis, et al.
Publicado: (2023)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
por: Mohty, Razan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4slkndcm99lonhqd6dl7cir68h